Receives Overwhelmingly Positive Dentist
Feedback and Unanimous Approval During Independently led
Trial
Results Demonstrate 100% Performance
Satisfaction and Recommendation of Wider Adoption among Dental
Practices
LAKE
FOREST, Calif., Dec. 12,
2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:
BIOL), the global leader in dental lasers, today announced the
successful completion of a trial program featuring the Waterlase
iPlus All Tissue laser conducted by six leading U.S. dentists. The
trial, led by an independent consultant, evaluated both the
potential return on investment (ROI) and clinical adoption of
BIOLASE's leading technology. The trial revealed unanimous doctor
satisfaction with the performance and desire to recommend the
purchase to others. This represented the second trial performed by
dentists at a dental service organization where all the
participants who evaluated the laser also purchased the
unit.
"We are very pleased with the results of our trial of the
Waterlase iPlus laser," said Dr. Steve
Fooshee, Advanced Laser Mentor/Educator Instructor. "The
laser is a valuable tool for dentists, and it has been
well-received by their patients. We are confident that the laser
will help dentists provide even better care to their patients."
The independent consultant and the dentists involved in the
trial assessed that this advanced technology allows providers to do
procedures they were not previously able to perform. This expanded
capability helped keep more patients and the potential revenue
associated with those patients within the practice and decreased
referrals to specialists. The Waterlase iPlus laser is a versatile
tool that can be used for a variety of dental procedures, including
tooth extractions, periodontal surgery, and cavity fillings. The
laser is also FDA-approved for use in treating periodontal disease.
After an evaluation of the potential ROI, all six dentists involved
in the trial elected to purchase the laser and stated that they
would recommend their colleagues do the same.
"The Waterlase iPlus laser is a significant advancement in
dental care," said Dr. Russell
Morrow, Chief Dental Officer for BIOLASE. "It is a more
precise and less invasive tool than traditional dental instruments,
and it can help to reduce pain and bleeding during dental
procedures. We are excited to partner with all dentists looking to
adopt this advanced technology so they can take care of their
patients at a higher standard and have a significant ROI on their
capital equipment purchase."
About BIOLASE
BIOLASE is a medical device company that develops, manufactures,
markets, and sells laser systems in dentistry and medicine.
BIOLASE's products advance the practice of dentistry and medicine
for patients and healthcare professionals. As of December 31, 2022, BIOLASE's proprietary laser
products incorporate approximately 259 patented and 24
patent-pending technologies designed to provide biologically and
clinically superior performance with less pain and faster recovery
times. BIOLASE's innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE's principal products are dental
laser systems that perform a broad range of dental procedures,
including cosmetic and complex surgical applications. From 1998
through December 31, 2022, BIOLASE
has sold over 45,500 laser systems in over 80 countries around the
world. Laser products under development address BIOLASE's core
dental market and other adjacent medical and consumer
applications.
For updates and information on Waterlase iPlus®, Waterlase
Express™, and laser dentistry, find BIOLASE online at
www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at
www.twitter.com/biolaseinc, Instagram at
www.instagram.com/waterlase_laserdentistry, and LinkedIn at
www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties, including statements,
regarding BIOLASE's expected revenue and revenue growth and beliefs
regarding its financial resources. Forward-looking statements can
be identified through the use of words such as "may," "might,"
"will," "intend," "should," "could," "can," "would," "continue,"
"expect," "believe," "anticipate," "estimate," "predict,"
"outlook," "potential," "plan," "seek," and similar expressions and
variations or the negatives of these terms or other comparable
terminology. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect BIOLASE's current
expectations and speak only as of the date of this release. Actual
results may differ materially from BIOLASE's current expectations
depending upon a number of factors. These factors include, among
others, the coronavirus (COVID-19) and the effects of the outbreak
and actions taken in connection therewith, adverse changes in
general economic and market conditions, competitive factors
including but not limited to pricing pressures, the anticipated
return on investment of the Waterlase iPlus All Tissue
laser, and new product introductions, uncertainty of customer
acceptance of new product offerings, including the Waterlase iPlus
All Tissue laser, and market changes, risks associated with
managing the growth of the business, and those other risks and
uncertainties that are described in the "Risk Factors" section of
BIOLASE's most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission (the "SEC") and any updates to
such risk factors in subsequent filings with the SEC. Except as
required by law, BIOLASE does not undertake any responsibility to
revise or update any forward-looking statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolase-successfully-concludes-waterlase-iplus-all-tissue-laser-trial-302013201.html
SOURCE BIOLASE, Inc.